Patents by Inventor William F. Goure

William F. Goure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
    Patent number: 9320793
    Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: April 26, 2016
    Assignees: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
    Inventors: William F. Goure, Franz F. Hefti, Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao, Alexander McCampbell, Min Xu
  • Antibodies, kit and method for detecting amyloid beta oligomers
    Patent number: 9310383
    Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: April 12, 2016
    Assignees: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
    Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Ningyan Zhang, Wei-Qin Zhao, Min Xu
  • METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42
    Publication number: 20150320860
    Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils, wherein the antibody is in combination with a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
    Type: Application
    Filed: December 4, 2013
    Publication date: November 12, 2015
    Inventors: William F. Goure, Franz F. Hefti, Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao
  • Antibodies, kit and method for detecting amyloid beta oligomers
    Patent number: 9176151
    Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: November 3, 2015
    Assignee: Acumen Pharmaceuticals, Inc.
    Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Nigyan Zhang, Wei-Qin Zhao
  • ANTIBODIES, KIT AND METHOD FOR DETECTING AMYLOID BETA OLIGOMERS
    Publication number: 20150260731
    Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: September 17, 2015
    Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Nigyan Zhang, Wei-Qin Zhao
  • Methods of modifying amyloid ? oligomers using non-peptidic compounds
    Patent number: 9006283
    Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: April 14, 2015
    Assignee: Acumen Pharmaceuticals, Inc.
    Inventors: Grant A. Krafft, Todd Pray, William F. Goure
  • Methods of restoring cognitive ability using non-peptidic compounds
    Patent number: 8962677
    Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: February 24, 2015
    Assignee: Acumen Pharmaceuticals, Inc.
    Inventors: Grant A. Krafft, Todd Pray, William F. Goure
  • Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers
    Publication number: 20130130288
    Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
    Type: Application
    Filed: July 9, 2012
    Publication date: May 23, 2013
    Inventor: William F. Goure
  • METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS
    Publication number: 20110098309
    Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers using acylhydrazide compounds.
    Type: Application
    Filed: July 11, 2008
    Publication date: April 28, 2011
    Applicant: ACUMEN PHARMACEUTICALS, INC.
    Inventors: Gary Charles Look, Lauri Schultz, Alexandre Mikhaylovich Polozov, Nikhil Bhagat, Jian Wang, David E. Zembower, William F. Goure, Todd Pray, Grant A. Krafft
  • METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS
    Publication number: 20090018084
    Abstract: Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from A?1-42 monomers.
    Type: Application
    Filed: July 12, 2007
    Publication date: January 15, 2009
    Inventors: Grant A. KRAFFT, Todd Pray, William F. Goure
  • METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS
    Publication number: 20090018218
    Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers from amyloid ?1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ?1-42 oligomers.
    Type: Application
    Filed: July 12, 2007
    Publication date: January 15, 2009
    Inventors: Grant A. Krafft, Todd Pray, William F. Goure
  • Substituted 2,6-substituted 1,2- or 1,6-dihydro pyridine compounds
    Patent number: 4908057
    Abstract: Disclosed herein are dihydropyridine dicarboxylic acid amide derivatives which are useful as herbicides, and herbicidal compositions and methods using same.
    Type: Grant
    Filed: August 1, 1988
    Date of Patent: March 13, 1990
    Assignee: Monsanto Company
    Inventors: John P. Chupp, Len F. Lee, William F. Goure, John M. Molyneaux
  • Methyl 4,4,4-trifluoro-3-oxo-butanethioate
    Patent number: 4785129
    Abstract: Disclosed herein is 4,4,4-trifluoro-3-oxo-butanethioate, a useful starting material in the preparation of pyridinedicarboxylate herbicides.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: November 15, 1988
    Assignee: Monsanto Company
    Inventors: William F. Goure, Len F. Lee
  • Process for preparing substituted benzotrichlorides
    Patent number: 4575565
    Abstract: The invention herein pertains to a novel process for making substituted benzotrifluorides.
    Type: Grant
    Filed: April 15, 1985
    Date of Patent: March 11, 1986
    Assignee: Monsanto Company
    Inventor: William F. Goure